{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9"],"submitter":["Rocco PRM"],"funding":["Conselho Nacional de Desenvolvimento Científico e Tecnológico","Financiadora de Estudos e Projetos"],"pubmed_abstract":["<h4>Background</h4>Nitazoxanide exerts antiviral activity <i>in vitro</i> and <i>in vivo</i> and anti-inflammatory effects, but its impact on patients hospitalized with COVID-19 pneumonia is uncertain.<h4>Methods</h4>A multicentre, randomized, double-blind, placebo-controlled trial was conducted in 19 hospitals in Brazil. Hospitalized adult patients requiring supplemental oxygen, with COVID-19 symptoms and a chest computed tomography scan suggestive of viral pneumonia or positive RT-PCR test for COVID-19 were enrolled. Patients were randomized 1:1 to receive nitazoxanide (500 mg) or placebo, 3 times daily, for 5 days, and were followed for 14 days. The primary outcome was intensive care unit admission due to the need for invasive mechanical ventilation. Secondary outcomes included clinical"],"journal":["Frontiers in medicine"],"pagination":["844728"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9043450"],"repository":["biostudies-literature"],"pubmed_title":["Nitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial."],"pmcid":["PMC9043450"],"pubmed_authors":["da Silva JDG","Barbosa LCV","Fernandes APSM","Caldeira DAF","Haag F","Fonseca FG","Luiz RR","Cabral AC","Nogueira CMB","Buchele KS","Pelosi P","Rocco PRM","Morais S","Araujo-Filho JA","de Oliveira MC","Tierno PFGMM","Sverdloff C","Moura AS","Reis JS","Junqueira AAF","Rabello E","Silva RGF","Cruz FF","Mamede MMS","Martins CM","da Costa LATJ","Lapa-E-Silva JR","Carajeleascow R","Junior JC","Soares CRP","Alvarenga PPM","Camargos VN","Felix NS","Franchini KG","Mattos-Silva P","Silva PL","de Avila RE"],"additional_accession":[]},"is_claimable":false,"name":"Nitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial.","description":"<h4>Background</h4>Nitazoxanide exerts antiviral activity <i>in vitro</i> and <i>in vivo</i> and anti-inflammatory effects, but its impact on patients hospitalized with COVID-19 pneumonia is uncertain.<h4>Methods</h4>A multicentre, randomized, double-blind, placebo-controlled trial was conducted in 19 hospitals in Brazil. Hospitalized adult patients requiring supplemental oxygen, with COVID-19 symptoms and a chest computed tomography scan suggestive of viral pneumonia or positive RT-PCR test for COVID-19 were enrolled. Patients were randomized 1:1 to receive nitazoxanide (500 mg) or placebo, 3 times daily, for 5 days, and were followed for 14 days. The primary outcome was intensive care unit admission due to the need for invasive mechanical ventilation. Secondary outcomes included clinical","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-04-08T13:21:06.895Z","creation":"2025-04-20T03:09:02.123Z"},"accession":"S-EPMC9043450","cross_references":{"pubmed":["35492335"],"doi":["10.3389/fmed.2022.844728"]}}